Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.73 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.73 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791211 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL25867 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL25866 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6758767 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16359955 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL24359130 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL14389708 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL767955 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4942099 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Hydrochloric Acid SCHEMBL29919822 | 0.99 | SLC28A1 (0.71) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117757791-A | Modified RNA agents with reduced off-target effects | 阿尔尼拉姆医药品有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-11913001-B2 | Immunisation of large mammals with low doses of RNA | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-02-27 | — | — | US | disclosed |
| US-20240060107-A1 | COMPOSITIONS AND METHODS FOR PREPARING CAPPED MRNA | GENSCRIPT USA INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2024036221-A2 | COMPOSITIONS AND METHODS FOR PREPARING CAPPED MRNA | GENSCRIPT USA INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-11898186-B1 | Compositions and methods for preparing capped mRNA | GENSCRIPT USA INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4308591-A1 | POLYPEPTIDES FOR COMPLEMENT INHIBITION | AFFILOGIC (FR) | 2024-01-24 | — | — | EP | disclosed |
| CN-110582283-B | Modified RNA agents with reduced off-target effects | 阿尔尼拉姆医药品有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20220331351-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TMPRSS6 AND IRON CHELATORS | SILENCE THERAPEUTICS GMBH (DE) | 2022-10-20 | — | — | US | disclosed |
| US-20220073967-A1 | PROCESS FOR THE ENZYMATIC SYNTHESIS AND AMPLIFICATION OF NUCLEIC ACIDS | AGCT GMBH (DE) | 2022-03-10 | — | — | US | disclosed |
| CN-103974724-B | Modified nucleosides, nucleotides and nucleic acids and uses thereof | 现代泰克斯公司 | 2019-08-30 | — | — | CN | disclosed |
| EP-3530755-A1 | METHOD FOR DISPLAYING THE PROGRESS IN THE AMPLIFICATION OF NUCLEIC ACIDS AND KIT FOR SAME | AGCT GmbH (DE) | 2019-08-28 | — | — | EP | disclosed |
| EP-3530756-A1 | METHOD FOR SELECTIVE AMPLIFICATION OF NUCLEIC ACIDS AND KIT FOR SAME | AGCT GmbH (DE) | 2019-08-28 | — | — | EP | disclosed |
| US-20190185914-A1 | PROCESS FOR THE AMPLIFICATION OF NUCLEIC ACIDS AND USE OF A KIT FOR CARRYING OUT THE SAME | AGCT GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| EP-3287528-A1 | METHOD FOR AMPLIFICATION OF NUCLEIC ACIDS AND KIT FOR SAME | AGCT GmbH (DE) | 2018-02-28 | — | — | EP | disclosed |
| CN-107709344-A | For treating the nucleoside analog of flaviviridae and cancer | 共晶制药股份有限公司 | 2018-02-16 | — | — | CN | disclosed |
| CN-107427529-A | N4-hydroxycytidine and derivatives and antiviral uses related thereto | 埃莫里大学 | 2017-12-01 | — | — | CN | disclosed |
| CN-107250146-A | Substituted nucleosides, nucleotides and the like | 艾丽奥斯生物制药有限公司 | 2017-10-13 | — | — | CN | disclosed |
| CN-106661076-A | Process for preparing substituted nucleotide analogs | 艾丽奥斯生物制药有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-103974724-A | Modified nucleosides, nucleotides and nucleic acids and uses thereof | modeRNA Therapeutics | 2014-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ADAR, SNRPE, ASGR1 | SLC28A1 1524/4885SLC28A2 1129/4885SLC29A1 1557/4885 |
| US-20220331351-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TMPRSS6 AND IRON CHELATORS | TMPRSS6, TMPRSS4, TFRC | SLC28A1 300/4885SLC28A2 307/4885SLC29A1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.